<DOC>
	<DOCNO>NCT00706615</DOCNO>
	<brief_summary>RATIONALE : Vaccines may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat woman previously treat metastatic breast cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Women With Previously Treated Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Characterize safety profile Ad-sig-hMUC-1/ecdCD40L vaccine woman metastatic breast cancer . - Identify tolerable , immunologically active dose level vaccine patient . Secondary - Evaluate immune function patient treatment vaccine . OUTLINE : Patients receive MUC-1 vector vaccine subcutaneously day 0 . After completion study treatment , patient follow monthly 9 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Women age 18 metastatic nonmeasureable adenocarcinoma breast marrow involvement . Elevated serum MUC1 level , measure CA 153 CA 2729 Stable disease ( define fluctuation &lt; 50U CA153 CA2729 value ) least 3 month either breastcancer therapy current therapy ( Tamoxifen , fulvestrant , exemestane , letrozole , anastrozole , bisphosphonates trastuzumab chemotherapy allow ) ability understand risk , benefit , procedure provide write informed consent . le 28 day prior enrollment since last surgery and/or radiation therapy . performance status &lt; =2 ECOG performance scale life expectancy great 12 month NYHA cardiac function Class I Class II normal baseline ECG . If ECG abnormal , patient must echocardiogram showing leave ventricular ejection fraction great low limit normal . patient radiographically assessable locally recurrent metastatic disease eligible 1 ) radiographic biopsy prove locally recurrent metastatic breast cancer past 2 ) currently ( study entry ) elevate serum MUC1 level ( measure CA 153 CA 2729 ) . Acceptable pulmonary function . questionable , pulmonary function test perform . negative serology hepatitis B , C HIV . red cell mean corpuscular volume &gt; 80 cu . mm , hemoglobin &gt; 8g/dl , platelet count &gt; 100,000/dl : AST , ALT , LDH &lt; 2 time Upper limit normal Serum creatinine &lt; 1.6 mg/dL woman child bear potential , Negative urine pregnancy test within 7 day registration willingness use approve contraceptive method participate trial . history bronchospasm asthma require inhaled oral steroid treatment Normal MUC1 ( CA 153 CA 2729 ) treatment steroid immunosuppressive medication ( condition ) within 30 day trial registration . history autoimmune disease ( e.g. , lupus , rheumatoid arthritis , psoriasis ) uncontrolled diabetes mellitus unable unwilling undergo repeat clinical evaluation diagnostic procedure unable sign inform consent . history malignancy , except squamous cell basal cell carcinoma skin cervical carcinoma situ . Concurrent systemic chemotherapy ( tamoxifen , aromatase inhibitor , fulvestrant , trastuzumab biophosphonates allow start 3 month prior trial registration evidence stable disease define . Chemotherapy must stop 3 month prior enrol trial ) . history ornithine transcarbamylase deficiency acute chronic viral , bacterial , fungal infection require specific therapy , unless acute therapy complete within past 14 day No underlying condition would contraindicate therapy study treatment ( allergies reagent use study ) history organ transplant allogeneic bone marrow transplant life threaten organthreatening disease expect require conventional therapy within 4 month . pregnant nursing female .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>